Erasca GAAP EPS of -$0.15 misses by $0.01

Erasca reported Q3 GAAP EPS of -$0.15, missing estimates by $0.01. The company's cash and marketable securities totaled $947.8 million as of September 30, 2026, up from $341.8 million at the end of 2025. Erasca believes its current cash position will support upcoming milestones.

Original reporting
Published Nov 12, 2026, 9:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ERAS
Bearish
medium confidence
Mentioned
$ERAS
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ERASBearishLow
01

Why it matters

The slight miss may cause short‑term price decline, but the company’s sizable cash balance may mitigate longer‑term concerns.

02

Market read

Earnings miss for a small‑cap biotech; potential short‑term downside.

03

What to watch

Strong cash position of $947.8 M could support upcoming milestones despite the EPS miss.

Relevance 6/10Novelty 5/10Timing: after-hours

Background

Erasca Inc. (ERAS) released its Q3 earnings, reporting a GAAP EPS of -$0.15 versus consensus of -$0.14.

Company-level read

Ticker impact

$ERASBearishMedium confidence
Context

Q3 GAAP EPS of -$0.15 missed consensus by $0.01.

Expected impact

likely downward pressure as investors price in the miss

Evidence & confidence

The miss is modest but earnings surprises often move small‑cap stocks sharply in after‑hours trading.

Market effects

Minimal impact on the broader biotech/health‑tech sector.

Limited to US small‑cap investors.

Low

Counterpoint

The miss is within a narrow range; the stock may rebound if cash runway remains strong.

Key entities

  • Erasca Inc.

    Biotech firm reporting Q3 earnings.

Related articles

Low

Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment

Tango Therapeutics and Erasca began a Phase I/II trial for ERAS-0015 and vopimetostat combo in lung and pancreatic cancer patients. The trial, sponsored by Tango, aims to find the max tolerated dose and assess safety, tolerability, and antitumour activity. Both companies believe the combo shows promise in treating RAS-driven cancers. ERAS-0015 targets RAS signalling, while vopimetostat inhibits PRMT5.

$ERASHighAI 8/10

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

Erasca (ERAS) received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic cancer. The designation allows for accelerated regulatory review. In a Phase 1 trial, ERAS-0015 showed a 57% response rate in pancreatic cancer patients. The company plans to initiate pivotal trials in 2027. Q2 2026 R&D expenses rose to $35.9M, and net loss widened to $44.1M. Erasca raised $632.5M in July 2026, leaving it with $384.3M in cash.

$ERASHighAI 8/10

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death

Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.